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Abstract
Background: Monocyte/macrophages (MO/MA), a polymorphic population of innate immune
cells, have the potential to mediate antitumor effects, and may also contribute to protumor effects.
A priming and post-chemotherapy schedule of the myeloid cell mobilizing and immune stimulatory
growth factor, granulocyte monocyte stimulating factor (GM-CSF, Leukine®) and the MO/MA
activating cytokine recombinant interferon gamma 1b (rIFN-γ1b, Actimmune®) has been
developed. The pre- and post-chemotherapy design is based upon known in vivo kinetics and
immune modulatory effects of these molecules. Carboplatin (Paraplatin®) was selected as the
cornerstone of treatment of epithelial ovarian cancer (EOC).
Methods: We studied hematopoietic and immunologic effects of GM-CSF and rIFN-γ1b before
and after carboplatin in patients with recurrent EOC. Potentially chemotherapy-sensitive patients
with recurrent measurable tumors received subcutaneous GM-CSF (starting at 400 µg/day) for 7
days plus subcutaneous rIFN-γ1b (100 µg) on days 5 and 7, before and after intravenous carboplatin
(area under the curve of 5). We performed standard hematologic assessment and monitored
monocyte (MO), dendritic cell, major cell subset counts, and antibody-dependent cell-mediated
cytotoxicity (ADCC) against a Her2neu+ tumor cell line, as well as selected plasma inflammatory
cytokine, chemokine and growth factor levels.
Results: Our analysis comprised only the first 3 months of treatment in the initial 25 patients.
Relative to pretreatment baseline values, white blood cell, neutrophil, MO, and eosinophil counts
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increased (P ≤ .001 for each); the proportion of platelets increased 9 days after the second (P ≤
.002) and third (P ≤ .04) carboplatin treatments; and the number of cells in the activated MO
subsets CD14+HLA-DR+, CD14+CD64+, and CD14+CXCR3+ increased (P ≤ .04 for each); plasma
levels of the proangiogenic interleukins 1α, 6, and 8 were lower (P ≤ .03 for each); M-CSF, a
product of activated MO/MA, was increased on day 9 (P = .007); and GM-CSF was increased in
plasma after GM-CSF administration (P ≤ .04). Quality of life measurements were reduced during
the GM-CSF/IFN-γ1b cycle while recovering at pre-chemotherapy baseline for FACT-G scores
only.
Conclusion: A novel regimen of GM-CSF plus IFN-γ1b administered to 25 EOC patients receiving
carboplatin increased myeloid cells, platelets and total activated MO populations during the initial
3 months; however, ADCC responses were not consistently enhanced during this period.
Introduction
In 2005 there will be an estimated 22,200 new cases of
epithelial ovarian cancer (EOC) and 16,210 deaths from
it in the United States, where EOC is the fifth most com-
mon cause of cancer-related death in women [1]. The 5-
year overall survival rate for patients with distant metas-
tases is 30.9% [2]. Platinum is the cornerstone of chemo-
therapy for EOC and, together with paclitaxel, is the most
frequently used first-line therapy [3,4]. Recurrences after
first-line chemotherapy are typically treated with carbopl-
atin, liposomal doxorubicin, a taxane, topotecan, gemcit-
abine, or etoposide [5], either as single agents or in
combination; single agents, including carboplatin, gener-
ate a response rate of 15% to 30%, and response rates are
higher after a treatment-free interval of ≥ 6 months [6]. A
7% improvement in survival was recently reported for car-
boplatin plus paclitaxel over "conventional" platinum-
based chemotherapy for recurrent EOC [7]. It remains
unknown, however, whether sequential use of these
agents might produce an equivalent or better survival out-
come.
Monocytes and macrophages (MO/MAs) are the most
common innate cell population in humans. Their role in
cancer patients is complex because they may either
enhance or impair immunity. Granulocyte-monocyte col-
ony-stimulating factor (GM-CSF) and recombinant inter-
feron gamma 1b (IFN-γ1b) are commercially available
cytokines that can modulate MO/MA activity. GM-CSF
can mobilize and mature myeloid cells, including MO/
MAs and dendritic cells (DCs) [8,9], whereas IFN-γ1b is
an activator of MO/MAs [10,11].
At biologically active doses, GM-CSF increases both neu-
trophil and MO counts to reach a plateau within 5 to 10
days [12]. When administered after chemotherapy, GM-
CSF reduces the duration of neutropenia and enhances
recovery. Prior studies have also demonstrated that intra-
venous "priming" with GM-CSF before chemotherapy
with anthracycline-based chemotherapy expands the pool
of myeloid progenitor cells and induces these cells to
become quiescent, which may enhance myeloprotection
with shortening the duration of severe neutropenia
[13,14].
GM-CSF may also stimulate the immune system by
enhancing antitumor effects by either innate or adaptive
antitumor immunity [15,16]. Thus, GM-CSF induces
destruction of tumor cells in vitro by stimulated peripheral
blood MOs [17], enhances DC maturation [18,19], and
has become an important component of certain vaccine
trials. In addition to other applications [20], GM-CSF has
shown promising results as an adjuvant in melanoma
[15] and in breast cancer [21]. GM-CSF has been com-
bined with other cytokines (e.g,. rIFN-α, interleukin 2 [IL-
2], and IFN-γ1b) and provided some treatment effects
against metastatic renal tumors and melanoma [22,23].
Optimum dosing and scheduling of these combinations
have not been determined. The addition of other
cytokines could have either synergistic or antagonistic
effects on GM-CSF's leukocytic proliferation and matura-
tional properties. GM-CSF alone can expand and prime
MOs destined to migrate to tissues as MAs, but other stim-
uli may be needed to mature or activate these cells more
fully. Such stimuli could be provided by other cytokines,
such as IFN-γ.
We designed a clinical trial of two immunomodulatory
cytokines, GM-CSF and IFN-γ1b, administered both
before and after carboplatin treatment in patients with
platinum-sensitive EOC that had recurred. We expected
that IFN-γ1b (administered during the latter half of the
GM-CSF cycle) would enhance the activation of MO/MAs
while GM-CSF would exert its proliferative effects on mye-
loid progenitor cells, minimizing any possible antiprolif-
erative effects from the IFN-γ1b. Here we report the
hematopoietic and myeloid immune cell effects during
the first three courses of a chemoimmunotherapy regimen
that consisted of GM-CSF and IFN-γ1b priming, carbopla-
tin, and post-carboplatin GM-CSF and IFN-γ1b. Detailed
analysis of the response and toxicity of the ongoing phase
II trial will be reported after the trial's completion.Journal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
Page 3 of 13
(page number not for citation purposes)
Patients and methods
Patient population
Patients eligible for inclusion in the study had Müllerian
carcinoma (primary epithelial ovarian, primary perito-
neal, or fallopian tube) that had initially responded to
platinum-based chemotherapy but recurred after a treat-
ment-free interval of ≥ 6 months; these tumors were con-
sidered "potentially platinum sensitive." Patients were
also required to have radiographically or clinically meas-
urable disease and CA-125 determinations. Adequate
hematologic, renal, and hepatic function was required as
defined by: absolute neutrophil count ≥ 1,500 cells/µL,
platelet count ≥ 100,000 cells/µL, serum creatinine ≤ 1.5
mg/dL, serum bilirubin ≤ 1.5 mg/dL, and aspartate
transaminase ≤ 2.5 × normal. A Zubrod performance sta-
tus score of ≤ 2 was also required. Patients could not have
received more than two prior chemotherapy regimens
(first-line platinum and platinum re-induction were
counted as one regimen). Other exclusion criteria
included prior immunotherapy, abdominal radiotherapy,
active heart or autoimmune disease, inflammatory bowel
disease, brain metastases, serum albumin ≤ 3 g/dL, or
known hypersensitivity to platinum agents. All patients
provided informed consent for participation in this IRB
approved study.
Cytokines
GM-CSF (Leukine®, specific activity 5.6 × 106 IU/mg; Ber-
lex Labs, Seattle, WA) was provided in vials containing
either 250 or 500 µg of the lyophilized powder and 40 mg
of mannitol, 10 mg of sucrose, and 1.2 mg of trometh-
amine. The cytokine was reconstituted with 1.0 mL of
either bacteriostatic water or sterile water at room temper-
ature.
IFN-γ1b (Actimmune®, specific activity 20 × 106 IU/mg
noncovalent form of dimeric protein; InterMune, Bris-
bane, CA) was provided in 0.5-mL vials containing 100 µg
of IFN-γ1b, 20 mg of mannitol, 0.36 mg of sodium succi-
nate, and 0.05 mg of polysorbate-20. The cytokine was
reconstituted in 0.5 mL of sterile water at room tempera-
ture.
Treatment regimen (Figure 1)
For each course of treatment, GM-CSF was administered
by subcutaneous injection in two 7-day cycles, one pre-
ceding and the other one following a fixed intravenous
dose of carboplatin (Paraplatin®, Bristol-Myers Squibb,
New York, NY) at an area under the curve of 5 (Calvert
Formula). Carboplatin was administered 48–60 hours
after the last dose of GM-CSF. For the post-chemotherapy
cycle, GM-CSF was started within 24–36 hours. For the
first and second cycles of GM-CSF, the dose started at 400
µg per day and escalated to 600 µg per day if the MO
count did not at least double and reach a level of 1,000
cells/µL. The GM-CSF dose could be reduced by 200 µg in
response to grade 3 major organ toxicity. IFN-γ1b was
administered by subcutaneous injection at a fixed dose of
100 µg on the fifth and seventh days of each 7-day cycle of
GM-CSF. No dose escalation of IFN-γ1b was permitted.
For subsequent courses, the pre-chemotherapy GM-CSF/
IFN-γ cycle was scheduled to start on day 20. For individ-
ual patients who had an absolute neutrophil count of
<1,000/µL or a platelet count of <100,000/µL, the subse-
quent treatment course was delayed until recovery of
absolute neutrophil count to ≥ 1,000/µL and platelet
count to ≥ 100,000/µL. After recovery, the second dose of
IFN-γ1b was omitted on each subsequent cycle of GM-CSF
in patients who developed significant neutropenia or
thrombocytopenia.
Patients who developed grade 3 allergic reactions were
treated with appropriate desensitization. Responses were
Treatment Schema Figure 1
Treatment Schema. Schematic of 28-day cycle for the administration of GM-CSF, rIFN-γ1b, and carboplatin.
Carboplatin was administered at an AUC of 5; GM-CSF was escalated from 400 µg to 600 µg subcutaneously, if monocytes did not both double and 
increase to ≥ 1000 cells/µl by day 9 after the first carboplatin administration.  IFNγ 0.1 mg was administered on day 5 & 7 of each 7-day cycle. 
X    X X   X X    X IFN-γ (SC) 
X-----------X X-------X X-----------X GM-CSF (SC)
X Carboplatin (IV)
20   24    26 2   6    8 1 -8     -4    -2  Treatment Day Journal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
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determined using modified World Health Organization
Response Evaluation Criteria in Solid Tumors (RECIST)
[24]. Up to three courses of the chemoimmunotherapy
regimen were required for the current assessment of
hematologic and immunologic effects.
Hematologic and blood chemistry monitoring
Before the start of each treatment course (i.e,. within 10
days before the first GM-CSF dose), the following were
checked for each patient: complete blood count, serum
creatinine, blood urea nitrogen, total bilirubin, aspartate
transaminase, alanine transaminase, electrolytes (Na, K,
Cl, and Mg), carbon dioxide, serum albumin, total pro-
tein, glucose, alkaline phosphate, lactate dehydrogenase,
and CA-125. A complete blood count was also obtained
on days -4, 1, 6, 9, 16, 21, 25, and 28 of the first treatment
course to monitor the pre and post-chemotherapy GM-
CSF/IFN-γ and on days 1, 9, 16, 21, and 28 of the second
and third treatment courses.
Immunologic monitoring
In the 12 patients who consented to optional studies,
peripheral blood was examined for the number and acti-
vation (or maturation) status of MOs and DCS and for in
vitro cytotoxicity experiments. Blood specimens were col-
lected on day -8 of the first treatment course before the
start of rIFN-γ1b treatment on day -4, before the start of
carboplatin treatment on day 1, and 9 days after carbopl-
atin treatment. Additional specimens were collected from
patients 3 months after the first treatment course was
begun. Peripheral blood (10 ml) was collected in ACD
(yellow top) vacutainer tubes The blood was centrifuged,
the plasma collected, and the mononuclear cells isolated
by Ficoll-Hypaque density gradient separation. In addi-
tion, for cytotoxicity studies, MOs were obtained from
anonymized normal donors through the blood bank as
controls.
Flow cytometry
MOs were identified within mononuclear cell prepara-
tions by flow cytometry as CD14bright  leukocytes or
CD14dim, CD45+  leukocytes. Mononuclear leukocytes
were further characterized for coexpression of HLA-DR,
CD64, and in some instances CD32 and CD32B. DCs
were identified directly in mononuclear cell preparations
of blood as lineage-negative, HLA-DR+  leukocytes by
using multidimensional flow cytometry [25,26]. Addi-
tionally, three-color labeling was performed to evaluate
the proportion and absolute numbers of CD11c+ pre-DC1
cells and CD123+ and pre-DC2 cell subsets [27]. Because
the maturation of DCs has been shown to be accompa-
nied by expression of CD83, lineage-negative, HLA-DR+
DCs were also tested for coexpression of this marker.
CD16+ and CD16- MOs have been shown to give rise to
DCs with different phenotypic and functional properties
[28]. Therefore, we also monitored this marker, as well as
CD2 (which is also expressed on a subset of MOs with the
potential to develop into DCs) [29]. For functional analy-
sis, MOs were isolated from mononuclear cell prepara-
tions by negative selection using immunomagnetic cell
sorting (Miltenyi Biotech, Bergisch Gladbach, Germany).
Staining for the CXCR3+ chemokine receptor was per-
formed on MO of selected patients using a PE-Cy5 labeled
mAb in conjunction with a PE labeled CD14 mAb.
Monocyte-mediated tumor cell cytotoxicity and Antibody-
Dependent Cellular Cytotoxicity (ADCC) assays
Enriched MOs from EOC patients undergoing treatment
were tested for their ability to induce the cytotoxicity of
tumor cells directly or in the presence of an antibody
capable of mediating ADCC by using a 3H-TdR release
assay we developed [30,31]. Briefly, washed SKOV3
human ovarian cancer cells, which are Her2neu+, were
labeled with3H-labeled thymidine (specific activity of 185
GBq/mmol; 50 µCi per 1.2 × 106 cells) in 10 mL of RPMI
1640 medium with heat-inactivated 15% fetal bovine
serum for 18 to 24 hours at 37°C in a humidified 5% CO2
incubator. Target cells were incubated with the human-
ized IgG1 antibody trastuzumab (Herceptin, Genentech,
San Francisco, CA), which recognizes the Her2neu surface
antigen, at a concentration of 5 µg/mL for 30 min at 37°C
in a shaking water bath. Sensitized target cells were
washed once and seeded with MO/MAs at an effects-to-
target ratio of 20:1 in 96-well U-bottom microtiter plates.
Purified MO were isolated from PBMC by negative selec-
tion, using a MO Isolation Kit and a MACS separator
(Miltenyi Biotec, Auburn, CA) as per manufacturer's
instruction. MOs obtained from non-MCSF stimulated
buffy coat samples were utilized as controls as previously
described [32] were incubated with murine 2B6 mono-
clonal antibody (kindly provided by MacroGenics, Rock-
ville, MD) that recognize CD32B at a concentration of 1.5
µg/mL in 1 × 106 cells for 1 hour. Plates were centrifuged
at 1,000 rpm for 1 min and incubated for 60 to 72 hours
at 37°C in a humidified 5% CO2 incubator.
Plates were spun down at 1,000 rpm for 5 min at 25°C,
and cell-free supernatants were transferred to scintillation
vials into which 5 mL of scintillation fluid was added
(Safety Solve; Research Products International, Mount
Prospect, IL). 3H-TdR release from target cells was counted
in a WinSpectral liquid scintillation counter (EG&G; Wal-
lac, Turku, Finland) for 1 min. The percent ADCC for MO/
MAs was calculated as (experimental release - spontane-
ous release) ÷ (maximum release - spontaneous release) ×
100, in which release values are in counts per minutes and
experimental release is counts from cell-free culture super-
natant from MO/MAs incubated with labeled tumor cells,
spontaneous release is counts from cell-free culture super-
natant from labeled tumor cells only, and maximumJournal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
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release is counts from cell-free culture supernatant from
lysed (5% Triton) labeled tumor cells only.
Plasma cytokine and chemokine measurements
Patients who consented to optional studies provided sam-
ples for measurement of plasma levels of cytokines IL-1α,
IL-1β, IL-6, IL-10, and TNF-α and the chemokine CXCL8
(IL-8). Plasma samples were taken on days -8, -4, 1, and 9
of the first course and at 3 months after the first treatment
course was begun. We used the Multiplex Bead chemolu-
minescence assay (Luminex, Austin, TX). The Multiplex
Bead Immunoassay is a multiplex assay that uses the
Luminex 100 analyzer (Austin, TX) and associated soft-
ware. Levels of multiple cytokines are measured in small
volumes by using fluorescently encoded microspheres
labeled with a distinguishable fluorophore that allows the
microspheres to be gated to a particular region by the
scanner. Antibodies specific for the cytokine or chemok-
ine of interest (Biosource International, Camarillo, CA)
are covalently linked to individual beads of a different flu-
orescent marker, thereby causing the cytokines or chem-
okine to bind to the specific complementary antibody-
coated bead and produce a unique fluorescent signature.
The minimum detectable levels using this method are:
IL1α, 5 pg/mL; IL-1β, 15 pg/mL; IL-6, 3 pg/mL; IL-10, 5
pg/mL; TNF-α, 10 pg/mL; CXCL8, 3 pg/mL; GM-CSF, 3
pg/mL; and M-CSF, 9 pg/mL.
Quality of life measurements
We used the Functional Assessment of Chronic Illness
Therapy-Biologic Response Modifier (FACT-BRM version
4) to assess changes in patients' quality of life. This ques-
tionnaire is a 44-item, cancer-specific measure of health-
related quality of life[33] It consists of 27 core items that
assess physical, social and family, emotional, and func-
tional well-being (FACT-G)[34] and 17 items that assess
disease and treatment-related issues specific to patients
receiving cytokine therapy (BRM)[35] Higher scores rep-
resent better quality of life. Recent research suggests a
change of 7 or more on the FACT-G total score indicates a
clinically significant change in quality of life[36] Patients
completed the 44-item FACT-BRM on days -8, -4, -1, and
9 of the first treatment course and on days -1 and 9 of the
second and third treatment courses.
Statistics
Wilcoxon rank sum tests were used to evaluate differences
in variables between individual time points. No correc-
tion was made for multiple testing. Statistical significance
was declared for p-values < 5%. SAS 9.1 was used for sta-
tistical analyses.
Results
Patient characteristics
Characteristics of the first 25 enrolled patients and their
tumors and prior treatment regimens are summarized in
Table 1. The median age at enrollment into the study was
62 years (range, 49–77 years). Most of the patients had
serous EOC that was ovarian in origin.
Hematopoietic effects
All 25 patients were evaluated for the hematopoietic
effects of chemoimmunotherapy. Chemistry analyses
were part of ongoing safety evaluations and are not
reported here in detail. The white blood cell (WBC) count
increased as expected after each GM-CSF cycle and peaked
6 days after the first dose of carboplatin (Figure 2A shows
means with 95% confidence intervals). The neutrophil
and eosinophil curves followed that of the WBC. The MO
count increased considerably after the first immuno-
therapy dose of GM-CSF and IFN-γ1b and on day 9 com-
pared with day -8 (Figure 2B). Prechemotherapy platelet
counts were statistically unchanged throughout the 3-
month study period, although they did increase signifi-
cantly on day 9 of the second (P = .002) and third (P ≤
.04) treatment courses (Figure 2C). When we compared
the values obtained on day -8 with those obtained on day
Table 1: Patient and Tumor Characteristics and Prior Treatment 
(N = 25)
Characteristic or Treatment No. of Patients
Zubrod performance status score
02 2
11
22
Race
White 22
Hispanic 2
Black 1
Primary tumor site
Ovary 22
Peritoneum 2
Fallopian tube 1
Histologic subtype
Serous 22
Clear cell 1
Endometrioid 1
Adenocarcinoma 1
First-line chemotherapy
Paclitaxel and carboplatin 23
Paclitaxel and cisplatin 1
Cisplatin and doxorubicin 1
Prior reinduction chemotherapy
Carboplatin 4
High dose with bone marrow transplantation 1
None 20
Prior hormonal treatment
Yes 10
No 15
Pelvic irradiation
Yes 1
No 24Journal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
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9, there were significant increases in total WBC, neu-
trophil, MO, and eosinophil counts at day 9 (P ≤ .001 for
all comparisons) (Fig. 2A–C).
Adjustments to treatment regimen
Sixteen of the 25 (64%) patients required a dose escala-
tion of GM-CSF from 400 to 600 µg. Twenty of the 25
(80%) patients met the target MO expansion of a dou-
bling from day -8 and >1,000 cells/µL. For two patients,
the dose was reduced from 600 to 400 µg because of tox-
icity, one before and one after the second course. In five of
the 25 patients (20%), the presence of neutropenia or
thrombocytopenia required that the day 7 dose of IFN-
γ1b not be given (4 after 2nd and 1 after 3rd course).
Immunologic cell alterations
For 12 of the 25 patients (48%), MO and DC subsets from
the first treatment course were examined as a function of
time (Figure 3A–E). Compared with pretreatment, on day
9, there were significant increases in the absolute number
of activated MOs, i.e,. HLA-DR+ cells (P = .04), cells with
high-affinity Fc receptor (FcR), i.e,. CD64+ cells (P = .01),
and cells with chemokine receptor, i.e,. CXCR3+ cells (P ≤
.02). There were no significant differences in the absolute
number of cells with low-affinity FcR (i.e,. CD16+ cells),
the absolute number of DCs (i.e,. CD11c+ and CD123+
cells), or the proportion of DC subsets. In addition, there
were no significant alterations in the numbers or propor-
tions of natural killer (i.e,. CD3-CD56+) cells over the
time period under study (data not shown). The propor-
tions of CD83+ DCs and CD2+ cells at day -8 were 1.4%
and 3.7%, respectively.
We also examined the CD32 MO population in a small
sample of four patients. On day -8, the mean (± SD)
number of CD32+ MO/MAs was 99.4 ± 0.4, and the mean
fluorescent intensity (MFI) was 145 ± 51. On day 9, the
mean number of CD32+ MO/MAs remained stable (99.9
± 0.2) but the mean MFI increased to 250 ± 45.
CD32B expression was also measured in a small sample of
two patients. The mean expression level was 36 ± 5% on
day -8 and 37.4 ± 0.2% on day 9, and the corresponding
mean MFI values were 16 ± 1% and 22 ± 1.4%.
MO-mediated tumor cell cytotoxicity and ADCC
Using the SKOV3 cell line and a 20:1 effects-to-target
ratio, we found overall lower in vitro MO-mediated tumor
cell cytotoxicity and ADCC with purified MOs from EOC
patients than with purified MOs from buffy coat samples
of normal subjects (Table 2).
Next, we compared the effect of GM-CSF treatment in vitro
on MO-mediated tumor cell cytotoxicity and ADCC in
samples from days -4, 1, and 9 of the first treatment course
and 3 months after the first treatment course was begun
with samples from pretreatment baseline (Table 3). There
was no significant effect of trastuzumab treatment overall,
although the number of patients tested was small and the
standard deviations large. More patients are needed to
assess whether GM-CSF treatment enhances the ability of
MOs from blood to mediate cytotoxicity or ADCC against
the SKOV3 cell line and at later time points as tumor bur-
den decreases in responding patients.
Plasma cytokine levels
Plasma levels of proinflammatory cytokines and the
chemokine CXCL8 are shown in Table 4. During the first
treatment course, (up to day 9), there were no statistically
significant alterations in CXCL8 levels. M-CSF, also a
product of MO/MA activation and which can be distin-
guished from GM-CSF by ELISA, was significantly
increased after MO maturation and activation on D9. In
contrast, at 3 months, plasma levels of IL-1α, IL-6, and IL-
8 were significantly decreased (P ≤ .033 for all three com-
parisons). GM-CSF levels were increased at each post
Hematologic Cell Counts as Function of Time in 25 patients Figure 2
Hematologic Cell Counts as Function of Time in 25 
patients. "Pre" – Study Baseline; "D" – day number preced-
ing first cycle (D-) or following (D+) carboplatin ("C") admin-
istration; "3M" – 3 months after initiation of therapy. Values 
are expressed as means and 95% CIs.
A
B
CJournal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
Page 7 of 13
(page number not for citation purposes)
treatment time point, suggesting that daily doses of GM-
CSF were associated with its detection in the circulation.
Preliminary toxicities
All 25 patients were evaluated for up to 3 months for tox-
icity. Treatment with the cytokines GM-CSF and IFN-γ1b
was well tolerated overall. Consistent with prior reports,
18 patients (72%) initially experienced grade 3 fatigue.
The fatigue did not recur in subsequent treatment courses
in any patient. One patient withdrew after the second
treatment course because of grade 3 fatigue and chest
tightness attributed to GM-CSF treatment. One patient
who developed grade 1 liver toxicity after the third treat-
ment course had to be removed from study after the fifth
treatment course. A liver biopsy examination suggested
drug-induced injury, but a viral etiology could not be
excluded since there was serologic evidence of prior
cytomegalovirus exposure. Six of the 25 patients required
carboplatin desensitization for an allergic reaction in the
second or third treatment course. Two patients experi-
enced a severe allergic reaction to carboplatin and were
removed from the study after the third and fourth treat-
ment course, respectively.
Immunologic cell alterations as a function of time in 12 patients Figure 3
Immunologic cell alterations as a function of time in 12 patients. Proportions and absolute numbers of activated 
monocytes (HLA-DR+); low affinity FcR (CD16+); high affinity FcR (CD64+); chemokine receptor (CXCR3+); DCs (CD11c+ 
and CD132+). D4- = post GM-CSF dose; D9+ = post GM-CSF plus IFNγ . Values are expressed as means with 95% CI. Note: 
Solid lines represent proportions and short dashed lines represent total or absolute counts. In Figure E, a long dashed line rep-
resents the proportion of CD123 cells.
A
B
C D
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Quality of life
In the first treatment course, there was no significant
change in FACT-G and BRM scores during cytokine
administration before the infusion of carboplatin (FACT-
G: day -8, 89; day -4, 86; day -1, 85; BRM: day -8, 54; day
-4, 53; day -1, 52). On day 9, there was a statistically and
clinically significant decrease in the FACT-G (90 v 81; P =
.009) and BRM (54 v 49; P < .02) scores compared with
day -8. The day before the start of the second treatment
course, the FACT-G scores returned to pretreatment base-
line values, but the BRM scores remained significantly
suppressed (54 v 50; P = .03). A similar pattern was seen
for the third treatment course. Symptoms specifically
related to BRM never returned to pretreatment baseline
levels.
Clinical response of patients through three treatment 
courses
Ten of the 25 patients (40%) had a clinical response, as
based on measurable disease, after completion of three
chemoimmunotherapy courses. Eighteen of these 25
patients (72%) had at least a 50% decline or normaliza-
tion of the CA-125 level from pretreatment baseline
through the end of the third treatment course, confirmed
by two post-treatment readings.
Discussion
As stated earlier, the purpose of this paper is to describe
the main hematologic and immunologic effects observed
in the initial 25 patients of the ongoing phase II chemo-
therapy clinical trial. Since the trial is ongoing, reporting
of response and toxicity information should be consid-
ered preliminary. To facilitate the statistical analysis, we
selected only the first 3 courses of treatment.
We have shown that 3 months of a prechemotherapy
priming schedule of daily subcutaneous GM-CSF for 7
days followed by a postchemotherapy schedule of subcu-
taneous GM-CSF for 7 days was reasonably well tolerated.
Increased absolute numbers of total WBCs, neutrophils
and MOs were observed. GM-CSF is the only approved
drug in the United States that can also stimulate non-gran-
ulocyte myeloid lineages such as MO/MAs and DCs.
The platelet count after three chemoimmunotherapy
courses was not significantly altered from the pretreat-
ment baseline count, but we thought it remarkable that
there were statistically significant increases in platelet lev-
els on day 9 of the second and third treatment courses. To
our knowledge, ours is the first report of a significantly
higher platelet count after GM-CSF treatment than before
GM-CSF treatment. This increase occurred at the same
time as the counts of the myeloid lineages were increased
and the levels of IL-6, which has platelet-stimulating
Table 2: MO-Mediated and Antibody-Dependent Cellular Cytotoxicity of Untreated MOs from EOC Patients and Normal Subjects
EOC Patients Normal Donor Samples*
MO antibody treatment No. Mean ± SD No. Mean ± SD P Value
None 8 0.8 ± 1.9 4 3.4 ± 3.2 .04
2B6 antibody 6 1.0 ± 2.3 4 8.5 ± 5.0 .02
trastuzumab 8 2.5 ± 3.1 5 11.5 ± 11.1 .06
trastuzumab + 2B6 antibody 6 4.1 ± 4.4 6 9.9 ± 5.9 .11
All experiments run with a concurrent control from 3 cryopreserved donor samples (see Methods).
Table 3: Mean Percentage ± SD Cytotoxicity during Treatment against the SKOV3 Ovarian Tumor Cell Line
Course 1
MO Treatment Day -8 Day -4 Day 1 Day 9 3 Months*
None 0.8 ± 1.9 (8)† 2.4 ± 3.6 (8) 1.3 ± 1.4(6) 2.8 ± 3.4 (7) 1.9 ± 0.9(3)
2B6 antibody 1.0 ± 2.3 (6) 2.3 ± 2.7 (6) 4.1 ± 3.2(4) 4.6 ± 3.0 (5) 4.6 ± 2.3(3)
trastuzumab 2.5 ± 3.1 (8) 3.7 ± 3.1 (8) 5.8 ± 4.7(8) 4.7 ± 5.4 (7) 4.3 ± 3.0(3)
trastuzumab + 2B6 a/b 4.1 ± 4.4 (6) 5.2 ± 3.3 (6) 10.8 ± 8.5(6) 7.6 ± 4.3 (6) 8.7 ± 5.0(3)
*Three months after first chemoimmunotherapy course was begun. † (n) = number of patients tested at each time period. P > .05 for day -8 vs each 
of the other categories (day -4, day 1, day 9, or 3 months).Journal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
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properties, were decreased. An early study had reported
higher platelet levels in a group of patients treated with
postchemotherapy GM-CSF than in another patient group
not treated with GM-CSF after chemotherapy[37] The fre-
quency of carboplatin hypersensitivity was not higher
than prior reports and probably reflects the number of
prior carboplatin courses. [38] In contrast, treatment with
macrophage colony-stimulating factor and IFN-γ has been
shown to produce grade 4 thrombocytopenia, grade 3
hepatic toxicity, and exacerbation of chronic obstructive
pulmonary disease[39]
In our study, the eosinophil count was increased on day 9
of all three treatment courses, but the count had returned
to pretreatment baseline levels 3 months after the chem-
oimmunotherapy regimen had been started. An earlier
study showed no association between the occurrence of
hypersensitivity reactions to carboplatin and eosi-
nophilia.[37]
One of the aims of our study was to determine whether
priming and postchemotherapy treatment with cytokines
GM-CSF and IFN-γ1b increases MO counts. We found that
MO counts increased significantly on day 9 of each of the
Table 4: Plasma levels of cytokines and growth factors before and during 3 months of treatment.
Cytokine or Chemokine Day* No. of Patients Mean Concentration (pg/mL) Change from Day -8 (pg/mL) P value†
IL-1α -8 13 43
-4 12 47 5.2 0.224
1 13 48 4.8 0.172
9 13 48 4.6 0.437
3M 11 29 -16.3 0.033
IL-1β -8 13 109
-4 12 115 8.0 0.295
1 13 122 13.6 0.052
9 13 125 16.4 0.069
3M 11 106 - 6.4 0.501
IL-6 -8 13 62
-4 12 76 12.3 0.166
11 3 7 2 1 0 . 2 0 . 1 6 4
91 3 7 9 1 6 . 3 0 . 0 9 4
3M 11 50 -18.4 0.014
IL-8 -8 13 12
-4 12 15 3.0 0.074
1 13 14 1.9 0.222
9 13 13 1.2 0.463
3M 11 8 - 4.6 0.019
IL-10 -8 13 9
-4 12 14 4.1 0.130
1 13 11 1.7 0.149
9 13 12 3.4 0.157
3M 11 9 - 1.2 0.418
TNF-α -8 13 150
-4 12 177 26.8 0.265
1 13 174 23.4 0.200
9 13 152 1.6 0.937
3M 11 121 -39.8 0.377
GM-CSF -8 13 2.9
-4 11 7.1 4.1 0.007
1 13 3.5 0.6 0.012
9 13 11.6 8.6 0.005
3M 11 5.7 2.6 0.041
M-CSF -8 13 519
-4 12 505 -26.0 0.847
1 13 610 90.8 0.153
9 13 863 343.9 0.007
3M 11 558 13.6 0.902
*Days -8, -4, 1, and 9 of the first chemoimmunotherapy course; 3M, 3 months after the first chemoimmunotherapy course was begun.
† P values not adjusted for multiple comparisons.Journal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
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three treatment courses and that MO values almost dou-
bled from day -8 to day 9 of each treatment course. Eighty
percent of the patients met the criteria of a doubling of the
MO count and >1,000 MOs/µL. From our results, daily
subcutaneous administration of 400 µg of GM-CSF
appears to be a reasonable starting dose and schedule in
this previously treated patient population. In another
study, although daily and twice daily GM-CSF dosing over
10 to 14 days was administered after carboplatin and
cyclophosphamide treatment, the addition of a twice
daily prechemotherapy priming schedule for 4 days
resulted in unacceptable toxicity in a small cohort of
patients.[40]
IFN-γ is the most potent clinically available activator of
MO/MAs. In adaptive immunity, IFN-γ participates in the
conversion of precytotoxic to cytotoxic effector T cells.
IFN-γ also enhances natural cell activity and can inhibit
tumor cell proliferation directly by a variety of mecha-
nisms[41] An in vitro study has suggested that IFN-γ plus
IL-4 can induce maturation of myeloid DCs to a predom-
inantly CD11C+  phenotype after GM-CSF administra-
tion[42] We did not observe statistically significant
alterations in DC numbers or maturation. IFN-γ -activated
MDM MOs may contribute to the destruction or inhibi-
tion of tumor cells by releasing tumor-inhibitory mole-
cules or by direct surface cell-to-cell interactions, such as
ADCC or phagocytosis, using the Fc-γ R pathway. Acti-
vated MO/MAs can produce oxygen radicals and nitric
oxide. In an early study, subcutaneous administration of
IFN-γ, even after a single dose of 100 µg, increased H2O2
production and Fc-γ R expression by MOs, whereas clini-
cal toxicity was low[43] In other studies, intravenous IFN-
γ at doses up to 100 µg also induced MO secretion of
H2O2,[44] although higher doses of IFN-γ (500 µg or
higher by continuous infusion) were associated with
immunosuppressive effects[45] We considered the 100-µg
subcutaneous dose appropriate for combination with
GM-CSF in the current study. IFN-γ has also shown activ-
ity against ovarian cancer in preclinical models[46] and in
patients receiving intravenous or intraperitoneal injec-
tions[47,48] A recently reported randomized trial of cispl-
atin and cyclophosphamide plus IFN-γ (administered
subcutaneously at a schedule of 0.1 mg for six doses per
chemotherapy course) resulted in increased time to tumor
progression among ovarian cancer patients and increased
survival compared with cisplatin and cyclophosphamide
alone[49] Because of the antiproliferative activity of IFN-
γ, dividing cells such as bone marrow progenitors might
be susceptible to frequently repeated systemic treatments.
Despite our limiting rIFN-γ1b to four doses per treatment
course, the dosing had to be reduced to one per GM-CSF
cycle in five susceptible patients.
GM-CSF plus rIFN-γ1b also produced alterations in the
activation cell surface marker phenotype of the MO pop-
ulation. Compared with pretreatment baseline, the pro-
portion and number of HLA-DR+ cells increased
significantly after GM-CSF treatment alone (day -4) or
with IFN-γ1b (day 9) (Fig. 3A). The numbers of CD64+
cells (i.e,. cells with high-affinity FcRs) also increased, but
there were no significant changes in CD16+ cells (i.e,. cells
with low-affinity FcRs). In contrast, the mean fluorescent
intensity (MFI) of CD32+ cells, which made up 100% of
MOs before treatment with GM-CSF, increased signifi-
cantly. Two previous studies had suggested that GM-CSF
can stimulate antitumor functions, such as ADCC, or MO-
mediated cytotoxicity[17,50] We found that after the
administration of GM-CSF and rIFN-γ1b, there was an
increase in the total number of MOs and activated subsets.
However, there was no statistically significant enhance-
ment of the MO-mediated cytotoxicity or ADCC effect
after treatment. These results might be due to the fact that
the CD16 low-affinity FcR is expressed on only about 10%
of MOs and was not significantly altered; however, MOs
also express other low-affinity FcRs, including CD32 and
its allotypes CD32A and CD32B. CD32A enhances
ADCC, whereas binding of CD32B blocks ADCC[51] We
have shown that CD32B, the inhibitory low-affinity FcR,
is expressed by approximately 30% of MO/MAs. The
reduced ADCC effect observed prior to the treatment com-
pared to values from normals suggest that these patients
might be exhibiting a defect in ADCC. We recently
described a similar defective ADCC effect utilizing macro-
phage-derived monocytes (MDM) from blood and ascites
of EOC patients [32], which is in agreement with the cur-
rent findings. It is possible that the tumor suppressive
effects might prevail, at least on certain MO-mediated
antitumor activity, when tumor burden and consequently
the cytokine suppressor environment is larger. This situa-
tion could be predicted to occur at earlier stages of chem-
otherapy induction or reinduction.
Previous work has demonstrated that systemic adminis-
tration of GM-CSF increases numbers of intraperitoneal
MAs, which could be important in ovarian cancer because
EOC is primarily a tumor of the peritoneal cavity[12] In
our study, the numbers of CXCR3+ MOs increased signif-
icantly on day 9 after administration of GM-CSF and rIFN-
γ1b (Fig. 3). CXCR3, which is present on activated MO/
MAs and on activated T cells,[52] binds several rIFN-γ1b-
induceable chemokines, including CXCL9/Mig, CXCL10/
IP-10, and CXCL11/I-TAC[53] These chemokines might
facilitate recruitment of activated leukocyte subsets to the
tumor site. IFN-γ- inducible chemokines may also induce
the proliferation of vascular pericytes that may induce
antitumor effects mediated through the common receptor
CXCR3. The CXC chemokines are a family of molecules
that can also regulate angiogenesis. The ELR+ moleculesJournal of Translational Medicine 2006, 4:16 http://www.translational-medicine.com/content/4/1/16
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are generally considered pro-angiogenic, while the ELR-
molecules are considered angiostatic[54] I-TAC has the
highest affinity for CXCR3,[55] and rIFN-γ1b can upregu-
late the production of Mig, IP-10, and I-TAC[52] Tumor-
associated MO/MAs have a range of effects that include
both pro- and anti-inflammatory responses. Activation of
MO/MAs by GM-CSF and IFN-γ might enhance antitumor
activity, but might also secrete products that are proang-
iogenic or contribute to growth and metastasis[56,57]
However, one might speculate that, as tumor burden
decreases during chemotherapy, activated MO/MA might
be polarized more towards antitumor effects as they are
released from the influence of the tumor.
Measurements of cytokines can provide some indication
of the patient's tumor environment and might also be use-
ful for monitoring immunomodulatory alterations of the
treatment. We showed here that there were no significant
increases in the plasma levels of the proinflammatory
cytokines IL-1α, IL-6, CXCL-8, or of TNF-α, even though
these proteins are produced by activated MO/MA. This
suggests that the combination of GM-CSF and IFN-γ1b
may not directly enhance production of these proang-
iogenic cytokines in vivo. In contrast, the plasma levels of
CXCL8 and IL1α were significantly decreased at 3 months
as a number of patients (72% showed a decline in CA125
values) were beginning to show responses.
The preliminary response data for 25 patients showed that
6 experienced a complete response and 4 experienced a
partial response. It was previously demonstrated that the
length of an initial response to platinum-based chemo-
therapy in ovarian cancer is predictive of the duration of
future responses[58] After completing accrual to the phase
II portion of the current trial, we will determine whether
this schedule of GM-CSF and IFN-γ1b plus carboplatin
enhances progression-free survival over prior courses of
treatment.
The quality of life component of the study demonstrated
little change in general and BRM-specific symptoms due
to the cytokine treatments. However, both aspects of qual-
ity of life were significantly affected by carboplatin treat-
ment. General aspects of quality of life returned to
pretreatment baseline levels between treatment courses,
whereas the BRM-specific symptoms remained sup-
pressed. This difference was most likely due to the residual
effects of carboplatin. Understanding the quality of life
effects of novel combinations of treatment is critical.
Examination of whether the BRM-specific symptoms
return to pretreatment baseline levels after treatment is
ended will be important to determine.
In conclusion, this novel regimen of GM-CSF, IFN-γ1b,
and carboplatin has an acceptable toxicity profile and sig-
nificantly increases blood levels of activated MOs, plate-
lets, WBCs, and neutrophils. Completion of the phase II
study will provide data on response, time to tumor pro-
gression in responders compared with prior treatments,
and toxicity and will provide an opportunity to determine
whether ADCC activity recovers in responding patients.
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